In Brief
Glycoprotein-deleted rabies virus is a powerful tool for neural circuit mapping.
Reardon et al. introduce the CVS-N2c
DG strain of rabies virus that allows for more efficient circuit mapping, monitoring, and manipulation.
INTRODUCTION
The quest to understand the organization and function of neural circuits has been aided by the development of genetic techniques that link neuronal connectivity and animal behavior. Recombinant viruses have emerged as powerful tools for analyzing circuit structure and function (Nassi et al., 2015) . When used with genetic markers for a large repertoire of neuronal types, recombinant transsynaptic viruses permit the construction of precise maps of synaptic input and output and provide an entry point for identification and manipulation of targeted neurons. The efficacy of such viruses depends on three main features: selectivity of expression in pre-defined neuronal classes, long-term neuronal viability, and efficient marking of neuronal inputs or targets.
Rabies virus (RABV)-based techniques have achieved particular prominence in circuit mapping (Coulon et al., 1989; Ugolini, 2010) because they enable retrograde, and for primary sensory neurons anterograde, transsynaptic neuronal tracing (Ugolini, 1995; Zampieri et al., 2014) . Moreover, the use of glycoprotein [G] deletion mutant RABV DG restricts viral budding and transfer, permitting selective mapping of first-order presynaptic neurons (Wickersham et al., 2007a (Wickersham et al., , 2007b . First-generation RABV DG tools, based largely on the attenuated vaccine strain SAD-B19 (Schnell et al., 1994; Wickersham et al., 2007b) , have two significant limitations: inefficiency of transsynaptic transfer and neurotoxicity with longer-term infection (Schnell et al., 2010; Callaway and Luo, 2015; Ghanem and Conzelmann, 2015 ) (see schematic, Figure 1A ). Toxicity could reflect high levels of viral gene expression combined with inherent mechanisms for stabilizing viral glycoprotein (Morimoto et al., 2000; Palusa et al., 2012) . Limitations to the efficiency of viral transfer could, in turn, be a function of weak viral neurotropism (Schnell et al., 2010; Hagendorf and Conzelmann, 2011) . To address these limitations, we have explored whether the use of a different RABV strain might reduce toxicity and achieve improved transsynaptic transfer-permitting more accurate analysis of the organization of neural circuits in the mammalian CNS. Many studies have documented laboratory RABV strains that exhibit varying degrees of pathogenicity. These strains range from virulent, highly neurotropic and neuroinvasive challenge viruses to apathogenic vaccine strains that have almost completely lost their neurotropism and neuroinvasiveness (Finke and Conzelmann, 2005; Jackson, 2013; Dietzschold et al., 2008) . These laboratory strains exhibit predictable tropism and transmission speed and are termed ''fixed'' viruses. The vaccine strain SAD-B19 was selected for its thermal stability, high titer in cell culture, low residual pathogenicity in small rodents, and immunogenicity in vivo (Geue et al., 2008) and was adopted as a neural circuit tracer (Kelly and Strick, 2000) . In a search for alternative RABV strains, we focused our attention on ''fixed'' strains that have been selected for neuronal affinity and rapid transport in vivo, potentially making them better suited than vaccine strains for the analysis of neural circuitry. Among these fixed strains, the challenge virus CVS-N2c exhibits strong neurotropism and reduced cytotoxicity (Morimoto et al., 1998; Ugolini, 2010; Hagendorf and Conzelmann, 2011) and has been used previously, in a replication-competent form, for multisynaptic circuit mapping in primates (Hoshi et al., 2005) . In addition, the availability of reverse genetically rescued CVS-N2c (Wirblich and Schnell, 2011) enables the design of replication-incompetent strains that can be rendered non-virulent and potentially more suitable for laboratory usage.
We report here the features of a glycoprotein-deficient CVSN2c DG strain derived from a virulent and highly neurotropic parental strain. Direct comparison with SAD-B19 DG reveals that CVS-N2c DG exhibits lower levels of neurotoxicity and enhanced retrograde transsynaptic transfer. The enhanced efficacy of CVS-N2c DG does not seem to be restricted to specific classes of neuron or circuits, in that we detected enhanced transsynaptic transfer in both corticostriatal and spinal premotor circuits. Neuronal viability is well maintained following infection by CVS-N2c DG variants that express proteins that permit monitoring and manipulation of neurons, as demonstrated in the septo-hippocampal pathway and in the parabrachial projection to the ventral tegmental area (VTA). The new CVS-N2c DG strain maintains compatibility with many of the helper viruses and complementation constructs used for SAD-B19 and thus constitutes a more effective reagent with which to probe the organization, physiology, and behavioral relevance of neural circuits in the mammalian CNS.
RESULTS

Recovery and Pseudotyping of CVS-N2c
DG
To provide a RABV strain for comparison with SAD-B19 derivatives, we explored the properties of a deletion mutant CVS-N2c strain, designated CVS-N2c DG , in which the glycoprotein gene (G) has been removed and complemented in trans by the deleted G gene, to permit retrograde monosynaptic transfer. The strong neurotropism of CVS-N2c may reflect the adaptation of virus to continued passage in mouse brain and cultured neuronal cell lines (Morimoto et al., 1998 (Morimoto et al., , 1999 . We rescued and amplified virus exclusively in Neuro2A neuroblastoma cells as a proxy for replication in primary neurons (see Experimental Procedures). Two Neuro2A-based lines were created for packaging: one expressing CVS-N2c(G) for use in amplification ( Figure 1B ) and the other expressing EnvA for use in pseudotyping ( Figure 1C ).
To monitor viral transfer and neuronal viability, we created variants of CVS-N2c DG expressing the fluorescent reporters dsRed or GFP ( Figures 1B and S1 ). We noted that the maximum The CVS-N2c deletion mutant was created in the manner pioneered by Wickersham et al. (2007a Wickersham et al. ( , 2007b attainable titer of CVS-N2c DG using our packaging cells was always lower than that achieved with SAD-B19 DG (Table S1 ).
Enhanced Transsynaptic Transfer of CVS-N2c DG Virus
We compared the efficiency of retrograde monosynaptic transfer of the CVS-N2c DG and SAD-B19 DG strains under similar infection conditions in cortico-striatal and spinal premotor circuits, assessing the spread of these viruses from primary infected, to transsynaptically infected secondary neurons. To achieve selective monosynaptic RABV transfer, we used two priming (helper) reagents introduced in trans, one to complement the deleted RABV glycoprotein (G) gene and the other to express the pseudotyping receptor TVA. To induce complementation, we developed Cre-conditional adeno-associated viruses (AAV) expressing RABV(G) and a nuclear marker, human histone2B-GFP (nGFP) (Kanda et al., 1998; Sun et al., 2014) . Two versions of the virus, designated AAV-FLEX-nGFP-2A-RABV [G] , were used to express either SAD-B19(G) or CVSN2c(G)-proteins identical in length but differing in 60 amino acid residues. After Cre recombination, both viruses directed glycoprotein expression to similar levels, assessed by immunofluorescence ( Figure S2 ). Selectivity was established by targeting neuronal subtypes for EnvA/TVA pseudotyped RABV DG infection (Wickersham et al., 2007b ) using a Cre-conditional virus, AAV-FLEX-TVA-mCherry, to achieve TVA receptor expression (Watabe-Uchida et al., 2012). . We used the maximum attainable titer for both the SAD-B19
DG and CVS-N2c DG strains (Table S1 ). Primary neurons were defined by co-expression of nGFP from RABV(G) priming virus and dsRed driven by RABV DG , whereas transsynaptically infected secondary neurons expressed dsRed alone. After an additional 10 days post-infection, primary and secondary neurons were counted, and the extent of transfer determined from the ratio of secondary to primary infection numbers.
In the corticostriatal pathway, medium spiny neurons (MSNs) of the striatum receive extensive excitatory input from cortical projection neurons (Gerfen and Bolam, 2010) , prompting us to compare the degree of retrograde transsynaptic transfer from striatal to cortical neurons. To restrict priming infection, we used mice expressing Cre-recombinase under the control of an adenosine receptor 2A (Adora2A) promoter, which is active in approximately half of all MSNs (Gong et al., 2007) (Figures 2B and 2C) Figures 2D-2F ).
MSNs represent a near-homogenous and densely interconnected neuronal population, such that local intra-striatal transfer of RABV is expected. But in this circuit, the determination of local viral transfer with current methods is not possible for two reasons. First, TVA-mCherry is not detectable with native fluorescence (Watabe-Uchida et al., 2012; Krashes et al., 2014) . Nevertheless, antibody amplification of the mCherry signal will likely cross-react with RABV-encoded dsRed, making primary versus secondary neuron identification ambiguous. Second, and more importantly, direct and transsynaptic infection by RABV DG cannot be distinguished within the population of TVA-expressing striatal cells, making secondary infection counts unreliable. This problem led us to evaluate the efficiency of transsynaptic viral transfer in a spinal circuit within which local transfer can be cleanly assayed, permitting the analysis of viral transfer as a function of axonal projection distance. We focused on spinal premotor circuits, where primary infected motor neurons transfer virus to premotor interneurons. Since motor neurons are anatomically and genetically distinguishable from surrounding spinal interneurons, the use of selective Cre mouse lines makes it possible to distinguish primary EnvA/TVA-labeled motor neurons from both local and distant secondary transsynaptically infected interneurons.
To target spinal motor neurons, we used mice expressing Cre under control of the choline acetyltransferase (ChAT) promoter. Paired TVA and RABV(G) priming viruses were injected into the ventral horn of L3 and L4 lumbar spinal segments, followed 2 weeks later by L3 and L4 injection of RABV DG -dsRed [EnvA] (Figure 3A) . Primary infection was limited to motor neurons, as identified by their distinct morphology and ventral position and nuclear expression of GFP by RABV(G) priming virus. We compared the total number of secondary infected neurons as a function of primary starter cell number for each strain and found that SAD-B19 DG was transferred to 7.0 ± 0.5 secondary cells (mean ± SEM; Figure 3E ), a number comparable to that found in previous studies using related helper viruses (Watabe-Uchida et al., 2012; Sun et al., 2014; Pollak Dorocic et al., 2014; Ogawa et al., 2014) . By comparison, each CVS-N2c DG primary neuron yielded 60.2 ± 16.3 secondary neurons ( Figure 3E ), close to an order of magnitude increase in the efficiency of total transsynaptic transfer. We also analyzed the transfer ratio as a function of the distance of secondary neurons from the injection site. At local lumbar levels, we detected a $80% reduction in primary infection by CVS-N2c
DG compared to SAD-B19
DG
, likely a result of the lower initial CVS-N2c DG titer (Figures 3B, 3E, and 3F; Table S1 ).
Despite this difference, the total number of secondary infected neurons detected at local lumbar levels was similar with both viral strains ( Figures 3B and 3F ), indicative of a $4-fold enhancement from CVS-N2c DG -mediated local transsynaptic transfer. But for more distant interneurons found in thoracic and cervical spinal cord segments and in the hindbrain, pairwise comparison revealed a 16-to 50-fold enhancement in efficiency of CVSN2c Figures 3C, 3D , and 3G).
Thus, transsynaptic transfer of the CVS-N2c DG strain exhibits an order of magnitude enhancement over SAD-B19
, and an especially strong improvement in transfer efficacy into spinal premotor neurons with distant somata.
Restricted Transsynaptic Transfer of CVS-N2c
DG
Resolving whether the transfer of CVS-N2c
DG is restricted to transsynaptic means is critical to the interpretation of anatomical tracing and connectivity maps. One report offered some evidence of synaptically restricted spread for SAD-B19 (Wickersham et al., 2007b) . But the lack of conclusive evidence that any RABV strain is transferred exclusively across synapses makes it crucial to resolve whether CVS-N2c virus spreads by additional, non-synaptic, means. We tested the exclusivity of CVS-N2c transfer at proprioceptive sensory synapses with spinal motor neurons, given that information on the normal pattern of connectivity in this circuit is available at high enough resolution to match experimental data with predictions about the selectivity of viral transfer. Within this circuit, proprioceptive sensory afferents make direct connections with spinal motor neurons that project to the same muscle (forming homonymous connections) and weaker connections to motor neurons innervating muscles with synergistic functions, termed heteronomous connections (Mendelsohn et al., 2015; Frank and Westerfield, 1983) . In addition, despite the proximity of sensory terminals and motor neuron dendrites, proprioceptive sensory neurons do not form direct connections with motor neurons that innervate antagonistic muscles (Figures 4A and 4B) (Eccles et al., 1957; Frank and Westerfield, 1983; Hongo et al., 1984; Mendelsohn et al., 2015) . The conservation of sensorymotor synaptic selectivity across mammalian species provided the basis for a ''homonymous versus antagonist'' assay to test the exclusivity of synaptic viral transfer in mice.
To examine the exclusivity of CVS-N2c DG transfer, we examined sensory-motor connectivity between ankle extensor gastrocnemius (GS) and ankle flexor tibialis anterior (TA) antagonist circuits. Motor neurons that innervate these two muscle groups possess dendrites that are interleaved in the ventral spinal cord ( Figure 4B ), permitting the detection of potential non-synaptic routes of transfer. We injected paired TVA and CVS-N2c(G) priming viruses into the GS muscle of ChAT-Cre mice, directing CVS-N2c(G) and TVA expression selectively in GS motor neurons ( Figure 4C ). Two weeks later, EnvA-pseudotyped CVS-N2c DG -dsRed was injected into spinal segments L3-L6, selectively infecting GS motor neurons. We then examined the pattern of fluorescent protein labeling in peripheral sensory endings derived from homonymous GS and antagonist TA group Ia proprioceptive sensory afferents.
We detected dsRed-labeled sensory endings in contact with intrafusal muscle spindle fibers in 75% of GS muscles but did not observe any dsRed-labeled spindle-associated sensory endings in the TA muscle (4 mice, n = 8 muscles; Figures 4D  and 4E ). This finding implies a tightly controlled and exclusively synaptic process of CVS-N2c DG transfer from motor neurons to sensory terminals that form monosynaptic contacts with their target motor neuron pool. (F and G) Plot of infection spread from primary to secondary neurons in six mice, three for each viral strain, at local lumbar (F) and (G) distant thoracic, cervical, and hindbrain levels.
Reduced Expression and Neurotoxicity of CVS-N2c
activity. To achieve this, we created RABV DG variants expressing humanized channelrhodopsin2 (hChR2), or a genetically encoded calcium indicator, GCaMP6f (Zhang et al., 2006; Chen et al., 2013) . In this set of experiments we controlled the duration of infection by injecting native-envelope RABV DG viruses such that they directly infected the terminals of projection neurons in corticostriatal and hippocampal-septal circuits.
To explore the utility of SAD-B19 DG and CVS-N2c DG as vectors for manipulating neural activity through hChR2 expression (Zhang et al., 2006) , we first analyzed levels of neurotoxicity for each strain. Injection of RABV DG into the dorsal striatum resulted in retrograde infection of cortical projection neurons. After 6 days, SAD-B19 DG -hChR2-YFP-infected neurons exhibited an aberrant neuronal morphology with distal dendrites exhibiting noticeable disruption and the surrounding neuropil containing neuronal debris ( Figures 6A and 6C ). In contrast, near-normal cortical neuronal morphology was observed 6 days after infection with CVS-N2c DG -hChR2-YFP ( Figures 6B and 6C ). We examined the ability of RABV DG -hChR2-YFP expression to confer photoexcitability, assaying responses over a 4-week period ( Figures 6D-6F ). Using SAD-B19 DG -hChR2-YFP virus, we detected few fully intact cortical neurons after 7 days of infection, precluding physiological analysis (six animals; Figure 6A ; data not shown). In contrast, photo-illumination at 473 nm wavelength of cortical neurons infected by CVS-N2c DG -hChR2-YFP reliably elicited action potentials in infected cortical neurons in acute forebrain slices ( Figures 6E and 6F ) for up to 28 days after infection. Spike frequency increased with the duration of viral expression over the first 10 days ( Figures  6F and 6G) . Moreover, recordings from nearby YFP off -uninfected cortical neurons revealed excitatory postsynaptic currents elicited by presynaptic photostimulation ( Figure 6H ). Stable whole-cell recordings from CVS-N2c DG -infected cortical neurons were obtained at a rate similar to that of uninfected neurons. Resting potentials (V m ) for infected and uninfected cells in the same animal were statistically similar over the infection period (À58.7mV ± 2.2, n = 7 versus À56.8mV ± 1.5, n = 16); without a clear trend for changes in V m as a function of infection time. These results document the efficacy of CVS-N2c DG in expressing hChR2 under conditions that permit optogenetic manipulation of neuronal activity. We next assessed the efficacy of CVS-N2c DG and SAD-B19 DG as monitors of neural activity through expression of GCaMP6f (Chen et al., 2013) . In this analysis we focused on hippocampal-septal circuits in which locomotion evokes robust hippocampal neuronal activity (Klausberger and Somogyi, 2008; Jinno et al., 2007) . We first assayed neurotoxicity of each RABV DG strain. Following injection of SAD-B19
DG
-GCaMP6f virus into the medial septum, infected hippocampal projection neurons exhibited marked signs of degeneration, most notably pronounced blebbing of neuronal processes 10 days after infection ( Figures 7A and 7C) . In contrast, septal neurons infected with CVS-N2c DG -GCaMP6f for 1 week exhibited near-normal morphology and only a modest disruption at 2 weeks ( Figures  7B and 7C) .
The activity of hippocampal-septal projection neurons after retrograde infection with CVS-N2c DG -GCaMP6f was determined through in vivo two-photon Ca 2+ imaging ( Figure 7E ). We detected hippocampal neuronal GCaMP6f-Ca 2+ transients in mice during treadmill locomotion, with a tight temporal coincidence in locomotor episodes and neuronal burst activity (Lovett-Barron et al., 2014) ( Figure 7G ). In addition, we found that the magnitude of treadmill-based locomotion-evoked Ca 2+ signals recorded from hippocampal-septal projection neurons was constant over the first 2 post-injection weeks ( Figure 7F ). Repeated recordings from identified neurons were possible for the entire usable duration of the cranial imaging window, at least 17 days post-infection. These findings establish that CVS-N2c DG confers durable, and physiologically non-disruptive, expression of GCaMP6f, permitting analysis of neuronal activity in vivo for at least several weeks.
CVS-N2c Expression Level Is Sufficient to Direct
Transgene Recombination CVS-N2c DG infection directs comparatively low levels of gene expression, and thus it is unclear whether Cre or Flpo proteins can be expressed at concentrations sufficient to exert efficient enzyme-mediated recombination. To address this issue we constructed -mCherry-2A-Flpo and -mCherry-2A-Cre driver viruses for CVS-N2c DG transduction. CVS-N2c In a similar manner, we investigated whether CVS-N2c DG directs Cre-mediated recombination. We injected CVS-N2c DG -mCherry-2A-Cre into the VTA of wild-type mice and in parallel injected a Cre-conditional AAV expressing GFP (AAV-FLEX-GFP) into the parabrachial nucleus (PBN) ( Figure 8C ). We found that $50% of mCherry + RABV-infected neurons expressed GFP ( Figure 8D) , consistent with the sparsity of infection of PBN neurons and indicative of the efficacy of Cre expression.
Together, these collected observations document that CVSN2c
DG rabies strain provides a more effective reagent than SAD-B19 DG when probing the organization and function of neural circuits in mouse brain and spinal cord (Table 1) .
DISCUSSION
Recombinant viruses facilitate the anatomical and functional analysis of mammalian neural circuits. We have explored the features of a recombinant strain of RABV, CVS-N2c presynaptic neurons, with an even greater enhancement in transfer to long-range inputs (Table 1) . CVS-N2c-based tools may therefore enable access to circuits that have so far proven refractory to RABV interrogation.
Enhanced Transsynaptic Tracing with CVS-N2c
DG Two major drawbacks in the application of attenuated RABVbased tools are high neurotoxicity (Morimoto et al., 1999) and inefficiency of transsynaptic transfer (Callaway and Luo, 2015) . Early generations of monosynaptic RABV-based vectors were primarily variants of the attenuated vaccine strain SAD-B19 (Schnell et al., 1994; Callaway and Luo, 2015; Ghanem and Conzelmann, 2015; Wickersham et al., 2007a Wickersham et al., , 2007b , which is weakly neurotropic and strongly immunogenic. By contrast, most virulent RABV strains are highly neurotropic and neuroinva- sive and, somewhat counter-intuitively, exhibit reduced immunogenicity and neurotoxicity by virtue of their sequestration in neurons and evasion of surveillance by immune cells (Schnell et al., 2010) .
The contrasting features of the SAD-B19 and CVS-N2c strains may stem from differences in growth and selection conditions. SAD-B19 was developed as a vaccine vector through serial passaging on non-neuronal cells. In contrast, CVS-N2c was developed through exclusive passaging in neonatal mouse brain and murine neuroblastoma cells as a challenge virus for testing RABV vaccines (Morimoto et al., 1998) . As a result, CVS-N2c is highly neuroinvasive;has selective tropism for neuronal cells, lower replication and protein expression; and has faster transport through the CNS (Bostan et al., 2010) . These traits diverge from those of SAD-B19, which has a lower tropism for neurons, but a higher affinity for non-neuronal cells and faster replication. The consequence of accelerated replication is a greater number of viral particles and a strong induced immune response (see Schnell et al., 2010; Ghanem and Conzelmann, 2015; Morimoto et al., 1998 and Morimoto et al., 1999 for discussion on relative tropism and virulence of different RABV strains). These observations led us to consider whether a more virulent RABV strain might hold promise for circuit analysis. In addition, the reverse genetic rescue of the virulent CVS-N2c strain (Wirblich and Schnell, 2011) has eased the task of generating a glycoprotein-deficient virus for use in monosynaptic tracing, as well as evading the biohazards inherent in working with virulent RABV.
We also provide evidence that CVS-N2c DG is transferred retrogradely through an exclusive transsynaptic route. The analysis of sensory-motor connectivity shows that CVSN2c DG does not transfer to nearby, non-connected, synapses-with the implication that the enhancement in secondary neuron labeling occurs via an increase in synaptic transfer, rather than adventitious viral infection. The strength of glycoprotein complementation vector (Callaway and Luo, 2015) , increased viral budding (Mebatsion et al., 1996) , enhanced glycoprotein neurotropism, reduced immunogenicity, and reduced viral toxicity (Schnell et al., 2010) may, separately or together, underlie the efficiency of RABV transfer and expression.
Of these variables, an increased neurotropism that maps to the viral glycoprotein is a plausible explanation for the increased transfer efficiency of CVS-N2c (Morimoto et al., 1998) . We and others have replaced the SAD-B19 glycoprotein with that of CVS-N2c when complementing SAD-B19 DG virus and found that it increases transsynaptic transfer, although not to the levels observed with fully complemented CVS-N2c DG virus (Kaifosh et al., 2013; Vé lez-Fort et al., 2014 ; T.R.R., A.J.M., T.M.J., and A.L., unpublished data). By implication, the CVS-N2c glycoprotein may enhance transsynaptic viral transfer. After CVS-N2c DG infection, the lack of infiltrating T cells, antibodies, and other antiviral immune effectors (Roy and Hooper, 2008; Schnell et al., 2010) may also increase the efficiency of viral transfer through the CNS. Finally, neuronal viability could extend the duration of competence for transsynaptic transfer, as well as maintain host accessory proteins that assist in RABV transfer. We note that our work relies on the same complementation strategy as Wickersham et al., (2007b) , and thus any improvements to that system, such as enhancement in TVA/EnvA selectivity or glycoprotein expression vectors, can easily be applied to the CVS-N2c strain. 
Selection of Appropriate RABV Vectors for Circuit Analysis
In our studies, CVS-N2c DG showed at least an order of magnitude enhancement in transsynaptic spread compared to the SAD-B19 DG strain and was particularly effective in transsynaptic infection of neurons with long-range projections. A similar improvement was seen in two distinct CNS circuits, suggesting that CVS-N2c DG lacks neuronal subtype constraints as a transsynaptic tracer. Thus for anatomical studies, CVS-N2c DG appears to have major advantages over SAD-B19 DG and other prominent vaccine strains (Mori and Morimoto, 2014) . Although it is conceivable that the transsynaptic efficiency of SAD-B19 could be improved with modifications to the complementation vectors (e.g., DeNardo et al., 2015) or the use of alternate complementation methods (Rancz et al., 2011; Wertz et al., 2015) , it is highly likely that the spread of CVS-N2c could be improved in the same way. Thus, the use of the CVS-N2c DG viral strain for anatomical studies has the potential to uncover aspects of neuronal connectivity inaccessible through the use of SAD-B19 DG .
The ability to manipulate and monitor the activity of neurons within large networks, on behaviorally relevant timescales, sets CVS-N2c DG apart from currently available RABV vectors. CVSN2c DG can drive tolerated levels of optogenetic activators, as well as recombinase proteins for selective recombination in presynaptic cells-opening the way for application of the full repertoire of conditional genetic tools in behaving animals. Previous studies have expressed optogenetic and recombinase proteins via SAD-B19 DG strains (Osakada et al., 2011) , but neuronal manipulations were typically restricted to short post-infection times, typically 5-7 days (Kiritani et al., 2012; Namburi et al., 2015) . We have found that use of SAD-B19 DG precludes functional analysis of neuronal activity, as a consequence of premature neuronal dysfunction or death. The high levels of protein expression achieved by SAD-B19 DG may be a major contributor to its viral toxicity (Morimoto et al., 1999 (Morimoto et al., , 2000 Schnell et al., 2010) . In particular, high expression levels of optogenetic proteins may facilitate cell death faster than would be observed when SAD-B19 DG is used to express relatively inert fluorescent proteins (Lin, 2011; Cetin and Callaway, 2014) . In contrast,
CVS-N2c
DG permits viable expression and long-term functional analysis using GCaMP6f or hChR2. Indeed, GCaMP calcium transients were detectable in hippocampo-septal neurons for up to 17 days, and cortical neurons expressing hChR2 under CVS-N2c DG control maintained normal cell physiology and functional responses for 28 days after infection. We cannot exclude that over longer post-infection times CVS-N2c DG may also induce neuronal dysfunction (Scott et al., 2008) , but the existing time-window opens potential new avenues for functional and behavioral experiments not available through use of SAD-B19 DG .
DG seems to have major advantages over SAD-B19 DG in terms of anatomical tracing and functional analysis of circuit organization. But there are circumstances whereby SAD-B19 DG remains a relevant reagent. The higher protein levels produced after SAD-B19 DG infection make it more suitable for use as an acute vector, when fast expression of the transgene is important. SAD-B19 DG drives protein expression just 1 day post-infection, which is not achievable with CVS-N2c
DG
. In addition, the higher SAD-B19 DG directed protein expression levels permit visualization of fine neuronal morphologies (Wickersham et al., 2007a (Wickersham et al., , 2007b . Moreover, the generation of viral particles in the laboratory is currently easier with SAD-B19 DG than with CVS-N2c
. Titers on the order of 1 3 10 9 infectious particles per milliliter can typically be achieved with SAD-B19
, in a period of 1 to 2 weeks. CVS-N2c DG titers used here were usually two orders of magnitude lower and generation of concentrated stocks of the virus can take 4 to 6 weeks. Given that full-length CVSN2c can be grown in laboratory to similar titers as SAD-B19, it is possible that future refinement of CVS-N2c DG packaging cells will improve attainable titers to the same level as SAD-B19 DG .
Our findings therefore establish CVS-N2c DG as an efficient monosynaptic retrograde reagent, one which overcomes many of the drawbacks inherent in the use of SAD-B19-based strains. Additionally, the enhanced ability of functional CVS-N2c DG variants to monitor and manipulate presynaptic neuronal populations may also make it easier to link the organization of neural circuits to their encoded behaviors. 
EXPERIMENTAL PROCEDURES
All animal procedures were performed in accordance with the regulations of the Institutional Animal Care and Use Committee (IACUC) of Columbia University.
Rescue of CVS-N2c DG Variants
DNA rescue plasmids for CVS-N2c were created previously (Wirblich and Schnell, 2011) . Four sequence differences were noted for CVS-N2c DG relative to previously published sequences (GenBank HM535790), though we have not explored whether these changes are new mutations or represent historical sequencing errors. Rescue plasmids for deletion mutant CVS-N2c . Supernatants from rescue cultures were collected for up to 10 days following the first appearance of virus. It is possible that more efficient RABV backbone plasmids could avoid the use of T7 (Ghanem et al., 2012) , but here we found that T7 polymerase was causal to the rescue. All culture of Neuro2A cells and derived lines took place in EMEM with 10% FBS without antibiotics. Cells were grown at 37C and 5% CO 2 until confluent, then held in extended harvesting conditions at 34 C and 3% CO 2 .
Harvested supernatant was filtered at 0.45 mm and stored at À80 C until used.
Packaging of CVS-N2c
DG
We considered that maintenance of the virus exclusively in murine neural tissue is likely important to the 1,000-fold improvement in neurotropism of the CVS-N2c strain compared to SAD-B19. Neuro2A cells stably expressing either N2c(G) or EnvA_cytG were created for viral amplification and pseudotyping ( Figures 1B and 1C ). The resulting cell lines are called N2A-N2c(G) and N2A-EnvA_cytG. For each variant, the glycoprotein gene was cloned into the MLV expression vector pCMMP-IRES-GFP, transfected into Gryphon retroviral packaging cells (Allele Biotech), and MLV-N2c(G)-IRES-GFP after filtering was used to infect Neuro2A cells. We found that Neuro2A cells are significantly less vital in culture than the traditional viral production cell line, BHK-21. Due to their limited vitality, we continued selection of these cells via FACS for more than 6 months. While titers produced are now useful for experimental purposes, they are still at least two orders of magnitude lower than titers produced from BHK-21 cells. However, the N2A-N2c(G) packaging line makes up much of the difference in viral counts by increasing effective titer likely due to improved neurotropism. Neuro2A cells expressing EnvA_cytG were created similarly, from a chimeric protein made from EnvA and the tail of N2c(G). Cross-pseudotyping (using EnvA_B19 to pseudotype CVS-N2c DG ) yielded very low titer, suggesting that the interaction of C-terminal glycoprotein and RABV M protein is critical for proper packaging. Amplification was performed by adding rescue supernatant to N2A-N2c(G) cells. Due to the relatively slow metabolism of cells in these conditions, we found it necessary to collect subsequent viral supernatants for up to 28 days in modified culture conditions of 34 C and 3% CO 2 . Virus for injection was spin purified by ultracentrifugation (2 hr, 20,000 RPM) and resuspension of viral The resultant virus only infects cells that express the avian TVA receptor, as tested using HEK293-TVA cells (Osakada et al., 2011) and, as designed, does not infect Neuro2A or HEK293 cells ( Figure 1C) .
All SAD-B19 DG variants were rescued and amplified per standard protocol (Wickersham et al., 2010) . Rescue plasmids were constructed from the ''Supercut'' rescue plasmid (Ghanem et al., 2012) . Titers assayed by fluorescent foci were 10 9 to 10 10 for native enveloped and 10 8 to 10 9 for EnvA pseudotyped.
Testing Specificity of Viral Infection and Expression
To test the selectivity of our AAV construct, we injected AAV driving the Credependent expression of N2c glycoprotein into the spinal cord of wild-type animals. 1 ml of the AAV-FLEX-nGFP-2A-RABV[G] was injected into the ventral horn at spinal segments L3-L6. Animals were sacrificed after 2 weeks, and the spinal cords were assayed for GFP expression. To test for contaminating wild-coat virions in our EnvA-pseudotyped CVS-N2c DG preparations,we injected 1.2 ml of these viruses into the ventral horn of spinal segments L3-L6. After 10 days animals were sacrificed and examined for expression of fluorescent protein.
Analysis of Spread
Mice expressing Adora2a-Cre (RRID: MMRRC_031168-UCD; Aged 12 to 16 weeks) were used for corticostriatal tracing. Mice expressing ChAT-Cre (RRID: IMSR_JAX:006410) were used for spino-motor neuron tracing. For all injections, animals were anesthetized using isoflurane and given analgesics. For corticostriatal injections, a craniotomy was created above dorsal striatum and injection pipette was lowered to target (0.75 mm AP, 2.2 mm ML, 3.3 mm DV). For AAV, we injected 39 nl of a 1:2 cocktail of AAV-FLEX-TVA_mCherry with AAV-FLEX-nGFP-2A-RABV [G] . Following 2 weeks of recovery and AAV expression, a secondary surgery was performed by the same technique and 300 nl of RABV DG (EnvA) was injected. All AAVs were serotyped 2+1, using established procedures (McClure et al., 2011) . Pairs of animals were sacrificed at 5, 10, and 15 days following RABV DG infection; brains were harvested and sliced at 100 mm by microtome for visualization. There was no significant difference in viral spread over the three differing infection periods. Imaging was done by confocal microscopy (Leica SP5 for corticostriatal, Zeiss 710 for spinal cord). All sections containing priming infection were imaged and double-labeled cells counted. Additionally, the locus and extent of priming infection was verified as the same, ±100 mm, for all six animals. For secondary labeling, slices at five AP coordinates (Bregma +2.8, +2.1, +0.5, +0.1, and À0.2) were viewed and dsRed+ cells in cortex manually counted.
For analysis of viral spread within the spinal cord, procedures were followed as above, but instead of craniotomy, injections were made into the ventral horn of the cord between L3 and L4 of 12-week-old ChAT-Cre mice. All secondary labeling was counted within lumbar, thoracic, and cervical spinal cord as well as the hindbrain (defined as caudal to Bregma À5.4) (Franklin and Paxinos, 2013) .
Gene Expression Analysis and Cytotoxicity
Neuro2A cells were infected with either SAD-B19 or CVS-N2c strains of RABV DG -GFP. For immunocytochemical analysis, Neuro2As were cultured in poly-l-lysine coated Labtek chamber slides and fixed with 4% paraformaldehyde in phosphate buffer after 2 or 4 days. Cultures were counterstained with neurotrace-647 (Invitrogen) and mounted in moviol. Images of infected and uninfected cells were taken using a Zeiss 510 confocal microscope with identical settings for each culture. In each field of view, the mean gray scale value for infected and uninfected cells was calculated, with uninfected cell values subtracted from infected as background values. Each culture was repeated three times with >50 cells analyzed per condition. Culture conditions were identical for analysis of PI incorporation. After fixation, cells were treated with 100 mg/ml RNase for 20 min at 37 C before addition of 500 nM PI for 3 min at room temperature.
Tissue Preparation for In Vitro Electrophysiological Recordings
Following surgical procedures above, C57 wild-type mice were infected with SAD-B19 or CVS-N2c strains of RABV DG -hChR2-YFP. 6-10 and 14 days after virus injection, we prepared coronal slices (350 mm) from the forebrain containing the injection sites, as described previously (Turi et al., 2015) . During recording, slices were maintained at room temperature and perfused at 1 to 2 ml per minute with artificial cerebrospinal fluid (ACSF) containing (in mM) 125 NaCl, 25 NaHCO 3 , 3 KCl, 1.25 NaH 2 PO 4 , 1 MgCl 2 , 2 CaCl 2 , 22.5 glucose, 3 sodium pyruvate, and 1 ascorbate and saturated with 95% O 2 and 5% CO 2 . Slices were visualized with Dodt contrast optics using a Zeiss Examiner Z1 upright microscope equipped with a 633 objective (1.0 NA; Zeiss) and twophoton scanning apparatus (Bruker Technologies).
In Vitro Electrophysiological Recordings and hChR2 Photostimulation
For whole-cell current-clamp recordings, we patched hChR2-expressing neurons in the secondary motor and cingulate cortices. The intracellular signals were amplified by a Dagan BVC-700A amplifier. Recording pipettes were pulled from borosilicate glass to tip resistances of $4-7 MU and filled with intracellular solution containing low Cl À (in mM) 140 potassium gluconate, 4 NaCl, 10 HEPES, 4 Mg 2 ATP, 0.3 Tris 2 GTP, 14 phosphocreatine, and 0.1 Alexa 594. Pipette capacitance was compensated, and the signals were filtered at 1-10 kHz and digitized at 50 kHz. hChR2 photostimulation was performed with a blue DPSS laser (473 nm, CrystaLaser) coupled to the microscope's two-photon scan-head (Lovett-Barron et al., 2012) . For testing the efficacy of the hChR2 expression, we ran a 5 Hz photostimulation protocol on the cells held at their resting membrane potential. After recording of five to eight traces, the number of photostimulation evoked spikes was divided by the number of the light stimuli.
Hippocampal Window Implant Following surgical procedures above, C57 wild-type mice were infected in the medial septum with SAD-B19 or CVS-N2c strains of RABV DG -GCaMP6f. Hippocampal window implant surgeries were performed as described previously (Kaifosh et al., 2013 , Lovett-Barron et al., 2014 . Briefly, we anesthetized mice with isoflurane and treated them with buprenorphine (0.1 mg/kg, subcutaneous) to minimize postoperative discomfort. We exposed the skull and drilled a 3-mm diameter circle centered over left dorsal CA1, matching the size of the cannula window to be implanted. We removed the bone and dura and then slowly aspirated cortex covering the hippocampus while constantly irrigating with chilled cortex buffer until the external capsule was exposed. Then we implanted the sterilized window implant by wedging it into place and secured the top of the cannula to the skull and stainless steel head-post with grip cement, leaving it to dry for 15-20 min before returning mice to the home cage (awake and mobile in 5-20 min). We monitored mice every 12 hr for 3 days after surgery, administering buprenorphine to minimize any signs of discomfort. Three days after the surgery, the animals were habituated to handling and head-fixation, and then we started to image the GCaMP6f-expressing cells.
In Vivo Cytotoxicity and Blebbing Analysis
Following injection of SAD-B19 or CVS-N2c strains of RABV DG -GCaMP6f into the medial septum, or RABV DG -hChR2-YFP into striatum to retrogradely infect corticostriatal neurons, we selected regions with similar numbers of infected neurons for analysis (n = 3 animals per condition; 10-15 neurons analyzed per region for hChR2; 2-10 neurons for GCaMP6f). Identical magnification was used for each sample, and the number of blebs was counted for each infected neuron.
Two-Photon Imaging
We use an in vivo a resonant galvo-based imaging system (Bruker) and an ultra-fast pulsed laser beam (Coherent; 920-nm wavelength) controlled with an electro-optical modulator to excite GCaMP6f through a 403 objective. Distilled water served to connect the water immersion objective with the cannula. Fluorescent light was detected with photomultiplier tube (green GCaMP6f fluorescence, GaAsP PMT) operated with PrairieView software. In vivo imaging was performed in head-fixed mice running on a linear treadmill (Kaifosh et al., 2013) . We tracked locomotor behavior by measuring treadmill wheel rotation, recorded as changes in voltage across an infrared photo-transistor as wheel spokes blocked light from an infrared LED. Time series were collected in green (GCaMP6f signal) channel at 512 3 512 at $30 Hz then underwent motion-correction as described in (Kaifosh et al., 2013) . Regions of interest (ROIs) were manually drawn over corrected time-series in Image J (NIH) to isolate the somata of cells of interest, and the extracted DF/F signals were aligned with the running signal.
Conditional Recombination
To analyze germline recombination by CVS-N2c DG-FLPo-mCherry, we injected 50 nl of virus into the ventral spinal at L3 of RCE-FRT mice (Sousa et al., 2009) . These animals contain a Frt-flanked STOP cassette prior to the GFP coding sequence and so report expression of Flp-recombinase. 10 days after CVS-N2c DG-FLPo-mCherry injection neurons in the thoracic spinal cord were imaged using a Zeiss 510 confocal microscope, and expression of mCherry, GFP, or both was noted. 
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